With several macroeconomic data pointing toward cooling inflation and the “soft landing” of the U.S. economy, market participants now see relatively very low chance of a hike in interest rates this month. It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.